Gastrointestinal stromal tumour

The Lancet

Volumn 382, Issue 9896, 2013, Pages 973-983

  Joensuu, Heikki ^a   Hohenberger, Peter ^b   Corless, Christopher L ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; DASATINIB; GROWTH FACTOR RECEPTOR; IMATINIB; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; IPILIMUMAB; MASITINIB; NILOTINIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMEN; ABSENCE OF SIDE EFFECTS; ANEMIA; ARTICLE; BIOPSY; BLEEDING; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARNEY COMPLEX; CARNEY STRATAKIS SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; ENDOSCOPY; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LAPAROSCOPY; LYMPH NODE DISSECTION; METASTASIS; MOLECULAR PATHOLOGY; MULTIGENE FAMILY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARAGANGLIOMA; PATHOLOGY; PATIENT SELECTION; PERIORBITAL EDEMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SARCOMA; SKIN DISCOLORATION; SMALL INTESTINE; STAIN; STEM CELL; STOMACH; SYSTEMIC THERAPY;

EID: 84884140350     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60106-3     Document Type: Review

References (140)

1. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011; 104: 865-73.
2. Corless CL, Barnett CM, Heinrich MC Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-78.
3. Min K.W. Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis. Ultrastruct Pathol 2010; 34: 174-88.
4. Joensuu H, Vehtari A, Riihimäki J, et al Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-74.
5. Kim KH, Nelson SD, Kim D.H., et al Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases. Anticancer Res 2012; 32: 923-37.
6. Woodall CE, Brock GN, Fan J, et al An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 2009; 144: 670-78.
7. Emile JF, Brahimi S, Coindre J.M., et al Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012; 29: 1765-72.
8. DeMatteo RP, Lewis JJ, Leung D, Mudan S.S., Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
9. Mazur MT, Clark HB Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-19.
10. Hirota S, Isozaki K, Moriyama Y., Hashimoto K, et al Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-56.
12. Demetri GD, von Mehren M, Blanke CD, et al Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
13. Aggarwal G, Sharma S, Zheng M., et al Primary leiomyosarcomas of the gastrointestinal tract in the post-gastrointestinal stromal tumor era. Ann Diagn Pathol 2012; 16: 532-40.
14. Ducimetière F., Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011; 6: e20294.
15. Nilsson B, Bümming P, Meis-Kindblom JM, et al Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103: 821-29.
16. Muccariani C, Rossi G, Bertolini F., et al Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007; 7: 230.
17. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1, 458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100: 162-68.
18. Chan KH, Chan CW, Chow W.H., et al Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol 2006; 12: 2223-28.
19. Cho MY, Sohn JH, Kim J.M., et al Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. J Korean Med Sci 2010; 25: 853-62.
20. Mikami T, Terada Y, Nakamura K., Okayasu I. The gastric hypercellular microleiomyoma as a precursor lesion for clinical gastrointestinal stromal tumors. Hum Pathol 1997; 28: 1355-60.
21. Agaimy A, Wünsch PH, Dirnhofer S., Bihl MP, Terracciano LM, Tornillo L. Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol 2008; 32: 867-73.
22. Kawanowa K, Sakuma Y, Sakurai S., et al High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37: 1527-35.
23. Agaimy A, Wünsch PH, Hofstaedter F., et al Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31: 113-20.
24. Abraham SC, Krasinskas AM, Hofstetter W.L., Swisher SG, Wu TT. "Seedling," mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol 2007; 31: 1629-35.
25. Corless CL, McGreevey L, Haley A., Town A, Heinrich MC KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160: 1567-72.
26. Rossi S, Gasparotto D, Toffolatti L., et al Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010; 34: 1480-91.
27. Beghini A, Tibiletti MG, Roversi G, et al Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92: 657-62.
28. Hirota S, Okazaki T, Kitamura Y., O'Brien P, Kapusta L, Dardick I. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000; 24: 326-27.
29. Isozaki K, Terris B, Belghiti J., Schiffmann S, Hirota S, Vanderwinden JM Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000; 157: 1581-85.
30. Li FP, Fletcher JA, Heinrich M.C., et al Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23: 2735-43.
31. Maeyama H, Hidaka E, Ota H., et al Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120: 210-15.
32. Nishida T, Hirota S, Taniguchi M., et al Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19: 323-24.
33. Chompret A, Kannengiesser C, Barrois M., et al PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004; 126: 318-21.
34. Pasini B, Matyakhina L, Bei T., et al Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab 2007; 92: 3728-32.
35. Carney JA, Sheps SG, Go V.L., Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977; 296: 1517-18.
36. Matyakhina L, Bei TA, McWhinney S.R., et al Genetics of Carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 2007; 92: 2938-43.
37. Janeway KA, Kim SY, Lodish M, et al Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011; 108: 314-18.
38. Carney JA, Stratakis CA Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 2002; 108: 132-39.
39. Dwight T, Benn DE, Clarkson A, et al Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol 2013; 37: 226-33.
40. Italiano A, Chen CL, Sung Y.S., et al SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer 2012; 12: 408.
41. Wagner AJ, Remillard SP, Zhang Y.X., Doyle LA, George S, Hornick JL Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2012; published online Sept 7. doi:10.1038/modpathol.2012. 153.
42. Zoller ME, Rembeck B, Oden A., Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997; 79: 2125-31.
43. Takazawa Y, Sakurai S, Sakuma Y., et al Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005; 29: 755-63.
44. Yantiss RK, Rosenberg AE, Sarran L, Besmer P., Antonescu CR Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol 2005; 18: 475-84.
45. Caterino S, Lorenzon L, Petrucciani N., et al Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol 2011; 9: 13.
46. Bümming P., Ahlman H, Andersson J., Meis-Kindblom JM, Kindblom LG, Nilsson B. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006; 93: 836-43.
47. Sepe PS, Moparty B, Pitman M.B., Saltzman JR, Brugge WR EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc 2009; 70: 254-61.
48. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-69.
49. Fletcher CD, Berman JJ, Corless C, et al Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65.
50. Sarlomo-Rikala M., Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-34.
51. West RB, Corless CL, Chen X, et al The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165: 107-13.
52. Novelli M, Rossi S, Rodriguez-Justo M, et al DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumors. Histopathology 2010; 57: 259-70.
53. Medeiros F, Corless CL, Duensing A, et al KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28: 889-94.
54. Lux ML, Rubin BP, Biase T.L., et al KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-95.
55. Heinrich MC, Corless CL, Duensing A, et al PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
56. Hirota S, Ohashi A, Nishida T., et al Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-67.
57. Blume-Jensen P., Claesson-Welsh L, Siegbahn A., Zsebo KM, Westermark B, Heldin CH Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. Embo J 1991; 10: 4121-28.
58. Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 2003; 23: 3067-78.
59. Yuzawa, S. Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007; 130: 323-34.
60. Rubin BP, Heinrich MC, Corless CL Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-41.
61. Kinoshita K, Hirota S, Isozaki K., et al Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 2004; 202: 80-85.
62. Agaram NP, Wong GC, Guo T, et al Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47: 853-59.
63. Miranda C, Nucifora M, Molinari F., et al KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 1769-76.
64. Doyle LA, Nelson D, Heinrich M.C., Corless CL, Hornick JL Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology 2012; 61: 801-09.
65. Celestino R, Lima J, Faustino A., et al Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors. Eur J Hum Genet 2012; published online Sept 5. doi:10.1038/ ejhg.2012.205.
66. Schneider-Stock R., Boltze C, Lasota J., et al High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003; 21: 1688-97.
67. El-Rifai, W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000; 60: 3899-903.
68. Ylipää A, Hunt KK, Yang J, et al. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 2011; 117: 380-89.
69. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: soft tissue sarcoma (version 2.2011). http://www.nccn.org/ professionals/physician-gls/ (accessed Oct 7, 2012).
70. Hohenberger P, Ronellenfitsch U, Oladeji O., et al Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97: 1854-59.
71. Agaimy A, Wünsch PH. Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 2009; 394: 375-81.
72. Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 2010; 34: 53-64.
73. Rege TA, Wagner AJ, Corless C.L., Heinrich MC, Hornick JL. "Pediatric-type," gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol 2011; 35: 495-504.
74. Hohenberger P, Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). Ann Surg Oncol 2010; 17: 2585-600.
75. Wang D, Zhang Q, Blanke C.D., et al Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012; 19: 1074-80.
76. Hohenberger P, Oladeji O, Licht T., et al Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 2009; 27 (SUPPL.): 548.
77. Eisenberg BL, Trent JC Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer 2011; 129: 2533-42.
78. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
79. Miettinen M, Makhlouf H, Sobin L.H., et al Gastrointestinal stromal tumors of the jejunum and ileum: a clinopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term-follow-up. Am J Surg Pathol 2006; 30: 477-89.
80. DeMatteo RP, Gold JS, Saran L, et al Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-15.
81. Jiang J, Jin MS, Suo J, Wang Y.P., He L., Cao XY Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. World J Gastroenterol 2012; 18: 2569-75.
82. Liang YM, Li XH, Li W.M., Lu YY Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors. World J Gastroenterol 2012; 18: 1664-71.
83. Rutkowski P, Bylina E, Wozniak A., et al Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37: 890-96.
84. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.
85. Wardelmann E, Losen I, Hans V., et al Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003; 106: 887-95.
86. Andersson J, Bümming P, Meis-Kindblom JM, et al Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006; 130: 1573-81.
87. Lagarde P, Pérot G, Kauffmann A., et al Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 826-38.
88. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-19.
89. Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-52.
90. Rossi S, Miceli R, Messerini L., et al Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35: 1646-56.
91. DeMatteo RP, Ballman KV, Antonescu C.R., et al, on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-104.
92. Joensuu H, Eriksson M, Sundby Hall K, et al Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). JAMA 2012; 307: 1265-72.
93. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine-kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011; 37: 75-88.
94. Corless CL, Schroeder A, Griffith D., et al PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-64.
95. Weisberg E, Wright RD, Jiang J, et al Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006; 131: 1734-42.
96. Cassier PA, Fumagilli E, Rutkowski P., et al Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18: 4458-64.
97. Heinrich MC, Griffith D, McKinley A., et al Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 4375-84.
98. Corless C, Ballman KV, Antonescu C, et al Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010; 28 (SUPPL.): 699.
99. Debiec-Rychter M., Sciot R, Le Cesne A, et al, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103.
100. Davies HE, Wathen CG, Gleeson FV The risks of radiation exposure related to diagnostic imaging and how to minimise them. BMJ 2011; 342: d947.
101. Verweij J, Casali PG, Zalcberg J, et al., for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials Group. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34.
102. Blanke CD, Demetri GD, von Mehren M, et al Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-25.
103. Blanke CD, Rankin C, Demetri G.D., et al Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-32.
104. Vanel D, Albiter M, Shapeero L., et al Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. Eur J Radiol 2005; 54: 118-23.
105. Choi H, Charnsangavej C, Faria S.C., et al Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-59.
106. Treglia G, Mirk P, Stefanelli A., Rufini V, Giordano A, Bonomo L. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. Clin Imaging 2012; 36: 167-75.
107. Plaat Be, Hollema H, Molenaar W.M., et al Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-20.
108. van Oosterom A.T., Judson I, Verweij J., et al, for the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-23.
109. Debiec-Rychter M., Sciot R, Le Cesne A, et al KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103.
110. Heinrich MC, Owzar K, Corless C.L., et al Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-67.
111. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247-53.
112. Reichardt P, Hartmann JT, Sundby Hall K, et al Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment: the first analysis in the SSGXVIII/AIO trial patient population. Eur J Cancer 2011; 47 (SUPPL. 2): 15.
113. LeCesne A, Ray-Coquard I, Buy B.N., et al, for the French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-49.
114. Heinrich MC, Corless CL, Demetri G.D., et al Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-49.
115. Demetri GD, Wang Y, Wehrle E., et al Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors: changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. J Clin Oncol 2009; 27: 3141-47.
116. Eechoute K, Fransson MN, Reyners A.K., et al A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012; 18: 5780-87.
117. Verweij J, van Oosterom A, Blay J Y, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-11.
118. Judson IR. Therapeutic drug monitoring of imatinib: new data strengthen the case. Clin Cancer Res 2012; 18: 5517-19.
119. Yoo C, Ryu MH, Kang B.W., et al A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. J Clin Oncol 2010; 28: 1554-59.
120. Janeway KA, Albritton KH, Van Den Abbeele AD, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009; 52: 767-71.
121. Chen LL, Trent JC, Wu E.F., et al A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64: 5913-19.
122. Antonescu CR, Besmer P, Guo T., et al Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90.
123. Heinrich MC, Corless CL, Blanke C.D., et al Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-74.
124. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005; 6: 249-51.
125. Liegl B, Kepten I, Le C., et al Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216: 64-74.
126. Hislop J, Mowatt G, Sharma P., et al Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer 2012; 43: 168-76.
127. Demetri GD, van Oosterom AT, Garrett CR, et al Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
128. Heinrich MC, Maki RG, Corless C.L., et al Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-59.
129. Demetri G, Reichardt P, Kang Y-K, et al Randomized phase 3 trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. J Clin Oncol 2012; 30: 632s (abstr).
130. DeMatteo RP, Maki RG, Singer S, Gonen M., Brennan MF, Antonescu CR Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-52.
131. Mussi C, Ronellenfitsch U, Jakob J., et al Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403-08.
132. Raut CP, Posner M, Desai J., et al Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-31.
133. Knowlton CA, Brady LW, Heintzelman RC Radiotherapy in the treatment of gastrointestinal stromal tumor. Rare Tumors 2011; 3: e35.
134. Kobayashi K, Szklaruk J, Trent J.C., et al Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol 2009; 32: 574-81.
135. Hasegawa J, Kanda T, Hirota S., et al Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 2007; 12: 212-17.
136. Jones RL, McCall J, Adam A., et al Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 2010; 36: 477-82.
137. Frilling A, Malago M, Testa G., et al Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. Transplant Proc 2010; 42: 3843-48.
138. Joensuu H, Fletcher C, Dimitrijevic S., Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-64.
139. Von Mehren M., Joensuu H, Demetri GD et al. Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol 2011; 29 (SUPPL.): 609.
140. Falchook GS, Long GV, Kurzrock R, et al Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-901.